| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
CPA targets the adenosine A1 receptor as a selective agonist. It has Ki values of 2.3 nM for human A1 receptors, showing high selectivity over A2A receptors (Ki=790 nM) and A3 receptors (Ki=43 nM). By activating A1 receptors, CPA modulates cellular signaling, neurotransmission, and other biological processes.
|
|---|---|
| ln Vitro |
In vitro, CPA is a selective adenosine A1 receptor agonist. Its ability to activate A1 receptors and modulate cellular signaling has been characterized in various cell-based assays. The compound's effects on neurotransmission, sperm capacitation, and other biological processes have been studied. Its selectivity for A1 over A2A and A3 receptors has been confirmed.
|
| ln Vivo |
In vivo, CPA has been shown to have anticonvulsant effects, delaying seizure onset and reducing mortality in NMDA-induced seizures in mice. It has significant analgesic effects in various pain models. The compound increases sperm capacitation in human spermatozoa studies. It is used to modulate cellular signaling and neurotransmission.
|
| Enzyme Assay |
In cell-free biochemical assays, CPA is evaluated for its binding affinity to adenosine A1, A2A, and A3 receptors. Receptor binding assays using membrane preparations from cells expressing the receptors are used to determine Ki values of 2.3 nM (A1), 790 nM (A2A), and 43 nM (A3). Its purity (>99%) and molecular weight (335.36 g/mol) are characterized using analytical techniques.
|
| Cell Assay |
Cellular assays for CPA involve evaluating its agonist activity at adenosine A1 receptors in cell lines expressing the receptor. The compound's ability to activate A1 receptor-mediated signaling is assessed. Its effects on cAMP accumulation and other downstream signaling events are studied. Its selectivity for A1 over A2A and A3 receptors is confirmed.
|
| Animal Protocol |
Animal models for CPA include models of seizures, pain, and sperm function. The compound has been shown to delay seizure onset and reduce mortality in NMDA-induced seizures in mice. It has significant analgesic effects in various pain models. Its effects on sperm capacitation have been studied.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for CPA show that the compound has a molecular weight of 335.36 g/mol with a molecular formula of C15H21N5O4. The CAS number is 41552-82-3. The compound appears as a white to off-white powder. It is soluble in DMSO (12.5 mg/mL) and water (2.5 mg/mL). Standard handling procedures for adenosine receptor agonists apply.
|
| Toxicity/Toxicokinetics |
The toxicity profile of CPA has not been extensively documented. As an adenosine receptor agonist, standard safety precautions for handling pharmaceutical research compounds apply. The compound is for research use only and not for human use.
|
| Additional Infomation |
CPA (N6-Cyclopentyladenosine) is a selective adenosine A1 receptor agonist with Ki values of 2.3 nM (A1), 790 nM (A2A), and 43 nM (A3). It has anticonvulsant, analgesic, and sperm capacitation effects. The CAS number is 41552-82-3.
|
| Molecular Formula |
C15H21N5O4
|
|---|---|
| Molecular Weight |
335.35834
|
| Exact Mass |
335.159
|
| CAS # |
41552-82-3
|
| PubChem CID |
657378
|
| Appearance |
White to off-white solid powder
|
| Density |
1.78g/cm3
|
| Boiling Point |
673.4ºC at 760 mmHg
|
| Flash Point |
361.1ºC
|
| Index of Refraction |
1.816
|
| LogP |
0.9
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
24
|
| Complexity |
438
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CN=C2NC1CCCC1
|
| InChi Key |
SQMWSBKSHWARHU-SDBHATRESA-N
|
| InChi Code |
InChI=1S/C15H21N5O4/c21-5-9-11(22)12(23)15(24-9)20-7-18-10-13(16-6-17-14(10)20)19-8-3-1-2-4-8/h6-9,11-12,15,21-23H,1-5H2,(H,16,17,19)/t9-,11-,12-,15-/m1/s1
|
| Chemical Name |
(2R,3R,4S,5R)-2-[6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~12.5 mg/mL (~37.27 mM)
H2O : ~2.5 mg/mL (~7.45 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.73 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.73 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (3.73 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9819 mL | 14.9094 mL | 29.8187 mL | |
| 5 mM | 0.5964 mL | 2.9819 mL | 5.9637 mL | |
| 10 mM | 0.2982 mL | 1.4909 mL | 2.9819 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03462914 | UNKNOWN STATUS | Brain Neoplasms | Assiut University | 2018-03-15 | ||
| NCT06447402 | RECRUITING | Drug: Normal saline Drug: Amphotericin B deoxycholate |
CPA Aspergilloma Chronic Pulmonary Aspergillosis |
Post Graduate Institute of Medical Education and Research, Chandigarh | 2024-06-03 | Phase 3 |
| NCT03027089 | UNKNOWN STATUS | Chronic Pulmonary Aspergillosis | Chinese PLA General Hospital | 2017-01 | ||
| NCT04535505 | WITHDRAWN | Diagnostic Test: Detection pathogenic pertussis by cross primer constant temperature amplification (CPA) and drug resistant genes of erythromycin by CRISPR technology |
Pertussis | Children's Hospital of Fudan University | 2022-07 | |
| NCT00313235 | COMPLETED | Biological: DC Vaccine and Cyclophosphamide | Malignant Melanoma Stage IV | Baylor Research Institute | 2006-03 | Phase 1 Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
